← Back to Clinical Trials
Recruiting NCT07167225

NCT07167225 Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07167225
Status Recruiting
Phase
Sponsor Roswell Park Cancer Institute
Condition Cigarette Smoking-Related Carcinoma
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2025-04-03
Primary Completion 2028-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 25 Years
Study Type OBSERVATIONAL
Interventions
Effectiveness of different recruitment approachesChoice of study completion locationsCannabis Engagement Assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2025-04-03 with a primary completion date of 2028-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and/or cannabis products in the blood and urine of young adult users as well as the cannabis and nicotine use behaviors of consumers.

Eligibility Criteria

Inclusion Criteria: * Young adult (18-25 years old). * Ability to read and write in English. * Participants must fall into one of the following groups (based on self-report): * Predominant e-cigarette consumer: defined as using nicotine-containing e-cigarettes daily for the past six months but not having used other nicotine containing products more than weekly or cannabis products for the past month. * Predominant cannabis consumer: defined as using cannabis at least 3x/week for the past six months in any form, including smoking, vaping, and oral use, with no more than weekly use of any nicotine or tobacco products. * E-cigarette-cannabis co-consumers: defined as daily use of nicotine e-cigarettes and use of cannabis at least 3x/week, including smoking, vaping, and oral use, for at least the past six months, with no use of other nicotine containing products more than weekly. * No self-reported diagnosis of kidney disease (current, or within the past year prior to the study visit). * Participants must understand the voluntary nature of this study and sign a written informed consent form before proceeding with study activities. Exclusion Criteria: * Individuals under the age of 18 or over the age of 25. * Currently pregnant or breastfeeding (female participants). * Unwilling or unable to follow protocol requirements

Contact & Investigator

Central Contact

ASK RPCI

✉ askroswell@roswellpark.org

📞 1-800-767-9355

Principal Investigator

Danielle Smith, PhD

PRINCIPAL INVESTIGATOR

Roswell Park

Frequently Asked Questions

Who can join the NCT07167225 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Cigarette Smoking-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07167225 currently recruiting?

Yes, NCT07167225 is actively recruiting participants. Contact the research team at askroswell@roswellpark.org for enrollment information.

Where is the NCT07167225 trial being conducted?

This trial is being conducted at Buffalo, United States.

Who is sponsoring the NCT07167225 clinical trial?

NCT07167225 is sponsored by Roswell Park Cancer Institute. The principal investigator is Danielle Smith, PhD at Roswell Park. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology